19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Both the Center for Disease Control and Prevention (CDC) and the Occupational Safety and Health Admi...
Read More >
Seyfarth Synopsis: The Federal Occupational Safety and Health Administration (OSHA) has cited Florid...
Read More >
BakerHostetler invites you to join us for an upcoming webinar, Federal Trade Commission - Antitrust ...
Read More >
On June 13, 2019, the Internal Revenue Service (IRS), Department of Labor and Department of Health a...
Read More >
We are seeing a significant increase in M&A activity in the renewable energy space in Australia as g...
Read More >
On May 5, 2020, the Georgia Court of Appeals affirmed a trial court summary judgment ruling dismissi...
Read More >